Related Experiment Video
Updated: Nov 10, 2025

Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain
Published on: February 12, 2016
Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and
J J McCabe1,2,3,4, E O'Reilly1, S Coveney1,2,5
1Health Research Board (HRB) Stroke Clinical Trials Network Ireland (SCTNI), Dublin, Ireland.
Insights
Inflammatory markers like C-reactive protein and fibrinogen are linked to recurrent stroke and major vascular events. Further research is needed to clarify their prognostic role and guide anti-inflammatory therapies.
Area of Science:
- Cardiovascular Medicine
- Neuroscience
- Biomarkers
Background:
- Anti-inflammatory therapies show promise in coronary disease but are understudied in stroke.
- The prognostic value of inflammatory markers post-stroke is unclear, and current guidelines do not recommend their routine use for risk stratification.
Purpose of the Study:
- To systematically review and meta-analyze the association between key inflammatory markers and the risk of recurrent stroke or major vascular events (MVEs).
- To evaluate the prognostic significance of C-reactive protein (CRP), interleukin-6 (IL-6), and fibrinogen in stroke survivors.
Main Methods:
- A systematic review of EMBASE and Ovid Medline databases was conducted up to October 1, 2019.
- Random-effects meta-analysis was performed on studies reporting comparable effect measures for CRP, IL-6, and fibrinogen.
- Included studies investigated the association between these markers and recurrent stroke or MVEs.
Main Results:
- Of 2,515 identified reports, 39 met eligibility criteria.
- C-reactive protein (CRP) was significantly associated with an increased risk of recurrent stroke (HR 1.14 per SD increase) and MVEs (HR 1.21 per SD increase).
- Fibrinogen also showed a significant association with recurrent stroke (HR 1.26) and MVEs (HR 1.31). Trends for IL-6 were observed but did not reach statistical significance.
Conclusions:
- Evidence suggests an association between inflammatory markers and post-stroke vascular recurrence, but significant methodological heterogeneity exists.
- Individual-patient data pooling and standardized methods are crucial to definitively establish the prognostic role of these markers.
- Improved understanding may aid patient selection for future anti-inflammatory therapy trials in stroke.
Background:
Recent randomised trials showed benefit for anti-inflammatory therapies in coronary disease but excluded stroke. The prognostic value of blood inflammatory markers after stroke is uncertain and guidelines do not recommend their routine measurement for risk stratification.
Methods:
We performed a systematic review and meta-analysis of studies investigating the association of C-reactive protein (CRP), interleukin-6 (IL-6) and fibrinogen and risk of recurrent stroke or major vascular events (MVEs). We searched EMBASE and Ovid Medline until 10/1/19. Random-effects meta-analysis was performed for studies reporting comparable effect measures.
Results:
Of 2,515 reports identified, 39 met eligibility criteria (IL-6, n = 10; CRP, n = 33; fibrinogen, n = 16). An association with recurrent stroke was reported in 12/26 studies (CRP), 2/11 (fibrinogen) and 3/6 (IL-6). On random-effects meta-analysis of comparable studies, CRP was associated with an increased risk of recurrent stroke [pooled hazard ratio (HR) per 1 standard-deviation (SD) increase in loge-CRP (1.14, 95% CI 1.06-1.22, p < 0.01)] and MVEs (pooled HR 1.21, CI 1.10-1.34, p < 0.01). Fibrinogen was also associated with recurrent stroke (HR 1.26, CI 1.07-1.47, p < 0.01) and MVEs (HR 1.31, 95% CI 1.15-1.49, p < 0.01). Trends were identified for IL-6 for recurrent stroke (HR per 1-SD increase 1.17, CI 0.97-1.41, p = 0.10) and MVEs (HR 1.22, CI 0.96-1.55, p = 0.10).
Conclusion:
Despite evidence suggesting an association between inflammatory markers and post-stroke vascular recurrence, substantial methodological heterogeneity was apparent between studies. Individual-patient pooled analysis and standardisation of methods are needed to determine the prognostic role of blood inflammatory markers and to improve patient selection for randomised trials of inflammatory therapies.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Intracellular Signaling Affects Focal Adhesions
Some...
Clot Retraction and Fibrinolysis
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Venous Thrombosis III: Interprofessional Care
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

